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The expression of arginine-vasopressin (AVP) is regulated by estradiol and testosterone (T) in
different neuronal populations by mechanisms that are not yet fully understood. Estrogen
receptors (ERs) have been shown to participate in the regulation of AVP neurons by estradiol.
In addition, there is evidence of the participation of ER in the regulation of AVP expression
exerted by T via its metabolite 5-dihydrotestosterone (5-DHT) and its further conversion in
the androgenmetabolite and ER ligand 3-diol. In this study we have explored the role of ERs
in the regulation exerted by estradiol and T on AVP expression, using the human neuroblas-
toma cell line SH-SY5Y. Estradiol treatment increased AVP mRNA levels in SH-SY5Y cells in
comparison with cells treated with vehicle. The stimulatory effect of estradiol on AVP expres-
sion was imitated by the ER agonist 4,4,4,-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol and
blocked by the ER antagonist, ICI 182,780, and the ER antagonist 1,3-bis(4-hydroxyphenyl)-
4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1hpyrazoledihydrochloride. In contrast, the ER
agonist 2,3-bis(4-hydroxyphenyl)-propionitrile reduced AVP expression, whereas the ER an-
tagonist 4-[2-phenyl-5,7-bis(trifluoromethyl) pyrazolo[1,5-a]pyrimidin-3-yl]phenol enhanced
the action of estradiol on AVP expression. T increased AVP expression in SH-SY5Y cells by a
mechanism thatwas dependent onaromatase but not on 5-reductase activity. The T effectwas
not affected by blocking the androgen receptor, was not imitated by the Tmetabolite 5-DHT,
and was blocked by the ER antagonist 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidi-
nylethoxy)phenol]-1hpyrazoledihydrochloride. In contrast, 5-DHT had a similar effect as the
ER agonists 2,3-bis(4-hydroxyphenyl)-propionitrile and 3-diol, reducing AVP expression.
These findings suggest that estradiol and T regulate AVP expression in SH-SY5Y cells through
ERs, exerting a stimulatory action via ER and an inhibitory action via ER. (Endocrinology 154:
2092–2100, 2013)
Arginine-vasopressin (AVP) is expressed by differentneuronal populations in the brain (1–3) and is in-
volved in different functions, including the control of
water homeostasis (4–7), blood pressure (8–10), ther-
moregulation (11–13), social behavior (3, 14, 15), and
stress response (16–19). Synaptic activity regulates the
firing of magnocellular AVP neurons (20), and in par-
ticular approximately 60% of the total number of syn-
apses in the supraoptic (SON) and paraventricular
(PVN) nuclei use -aminobutyric acid as neurotrans-
mitter (21). In addition, several endocrine factors, in-
cluding gonadal hormones, may participate in the reg-
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ulation of AVP neurons and AVP expression. Both
estradiol and T have been shown to regulate AVP ex-
pression in the brain (22–24). In particular, estradiol is
able to regulate AVP expression in the PVNofmalemice
(25), and it increases AVP plasma levels in ovariecto-
mized female rats (22, 26), whereas T regulates AVP
expression in the SON (27) and in the bed nucleus of the
stria terminalis (28) of male rats.
The mechanisms involved in the regulation of AVP
expression by T and estradiol are not fully clarified.
Estrogen receptors (ERs) have been shown to partici-
pate in the regulation of AVP neurons by estradiol (29–
32). ER is expressed in AVP neurons of the SON and
the PVN (33–35), whereas ER is expressed in the me-
dial preoptic area (31), lateral septum, and medial
amygdala (32), important targets for the parvocellular
AVP system.Moreover, ER seems to be involved in the
regulation of AVP expression in the SON and PVN of
female rats (30, 36), probably through a mechanism
mediated by afferent neurons projecting to the SONand
PVN and expressing ER (7, 30, 37, 38). However,
there is also evidence of T participation in the ER reg-
ulation of AVP expression via its metabolite 5-dihy-
drotestosterone (5-DHT) and its further conversion in
3-diol, which is a ligand of ER (39, 40).
In this study we explored the role of ERs in the regu-
lation exertedby estradiol andTonAVPexpression, using
the human neuroblastoma cell line SH-SY5Y. These cells
express ERs (41) and aromatase (42). In the present study,
we determined that SH-SY5Y also expresses AVP and is
therefore a good model to assess the role of ERs in the
action of T and estradiol onAVP expression.Our findings
indicate that both estradiol and T exert stimulatory and
inhibitory actions on AVP mRNA levels acting through
ER and ER, respectively.
Materials and Methods
Cell culture
ThehumanSH-SY5Yneuroblastoma cell linewas used in this
study. SH-SY5Y cells are genetically female. The line was pur-
chased fromAmerican Type Culture Collection (Manassas, Vir-
ginia) andwas cultured in DMEM-F12 supplementedwith 10%
fetal bovine serum. Cells were passaged twice perweek andwere
not used after 10 passages.
Treatments
After 12 hours of serum starvation using serum-free me-
dium, cells were incubated with fresh serum-free medium con-
taining vehicle (ethanol); 17-estradiol (from 1010 to 107
M; Sigma, Madrid, Spain); ICI 182,780 (109 M; Sigma);
4,4,4,-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT;
from 1010 to 107 M; Tocris, Madrid, Spain); 1,3-bis(4-
hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phe-
nol]-1hpyrazoledihydrochloride (MPP; from109 to 106M;
Tocris); 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN; from
1010 to 107 M; Tocris); 4-[2-phenyl-5,7-bis(trifluorom-
ethyl) pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP; from
109 to 106 M; Tocris); T (from 109 to 105 M; Sigma);
5-DHT (from 1010 to 106 M; Sigma); 3-diol (5-andro-
stane-3,17-diol (from 109 to 106 M; Sigma); flutamide
(from 109 to 105 M; Sigma); letrozole (1010 to 107 M,
Novartis, Basel, Switzerland); and/or finasteride (1010 to
106 M; Sigma).
RNA isolation and quantitative real-time PCR
After 24 hours, cells were lysed and total RNA was ex-
tracted using the illustra RNAspin mini-RNA isolation kit
(GE Healthcare, Buckinghamshire, United Kingdom) as per
the manufacturer’s instructions to measure AVP, ER, and
ER mRNA levels. 18S rRNA was used as the control house-
keeping gene. Deoxyribonuclease digestionwas carried out on
a column using the same kit. The first cDNA strand was syn-
thesized using all RNA extracted by reverse transcription in a
final volume of 15 L using the RevertAidTM HMinus first-
strand cDNA synthesis kit (MBI Fermentas, Bath, United
Kingdom) according to the supplied protocol. After reverse
transcription, the cDNA was diluted 1:4 and 5 L were am-
plified by real-time PCR in 20 L using SYBR Green master
mix (Applied Biosystems, Foster City, California) in an ABI
Prism 7500 sequence detector (Applied Biosystems), with con-
ventional Applied Biosystems cycling parameters (40 cycles of
95°C, 15 seconds, and 60°C, 1 minute).
Primers for human AVP, human androgen receptor (AR),
and human 18S were designed using Primer Express 1.0 (Ap-
plied Biosystems) and Amplify software. Primers for human
ER and human ER were used as previous described in our
group (43). See Table 1 for transcript references and primer
sequences.
After amplification, the size of the quantitative real-time PCR
products was verified by electrophoresis on 2% (wt/vol)
ethidium bromide-stained agarose gel, and the identity of PCR
productswas ascertained by sequencing. Bandswere excised and
Table 1. Transcript References and Primer Sequences Used for Quantitative Real-Time-PCR
Transcript Forward Primer (5–3) Reverse Primer (5–3)
AVP (NM_000490.4) TGTGTGCACCAGGATGCCT TCAGCTCCAGGTCGGACAT
18S (NR_003286.1) CGCCGCTAGAGGTGAAATTCT CATTCTTGGCAAATGCTTTCG
ER (NM_000125.1) GCTTCGATGATGGGCTTACTGA ATGCGGAACCGAGATGATGT
ER *(AF051427) AGATTCCCGGCTTTGTGG GCTTCCGGCTGCTGTCA
AR transcript 1 (NM_000044.3) CCCATCCCCACGCTCGCATC CATGCAGGCTCGCCAGGTCC
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cDNA was purified using the QIAquick PCR purification kit
(QIAGEN Gmbg, Hilden, Germany). One hundred nanograms
of AVP, AR, ER, and ER mRNA samples were sequenced
(Automatic Sequencing Center, Consejo Suerior de Investiga-
ciones Científicas, Madrid, Spain) with the same sense and
antisense primers. The obtained sequencewas alignedwith the
expected sequence obtained from the GenBank. In addition,
dissociation curve analysis was also performed after each PCR
to ensure that a single product and no primer-dimers were
present. All reactions were performed in triplicate. The rela-
tive mRNA expression level was calculated using the CT
method, using ribosomal 18S RNA as the endogenous RNA
control to correct for the amount of total RNA used in each
PCR reaction.
Statistical analysis
Data were analyzed via 1-way ANOVA, followed, when
appropriate, by a post hoc analysis with the Bonferroni’s test.
The SPSS 17.0 software (SPSS Inc, Chicago, Illinois) was used
for calculating probability values. P  .05 was considered
statistically significant. Data are represented as the mean 
SEM. Results of the statistical analyses are shown in the figure
legends.
Results
Characterization of AVP, ER, and AR expression in
SH-SY5Y neuronal cells
SH-SY5Ycellswere initially tested for the expressionof
AVP, ERs and AR. Real-time PCR indicated the expres-
sion of AVP, ER, and ERmRNA in this cell line (Figure
1). In contrast,we did not detectARmRNA inour cells (as
positive control we used the prostate adenocarcinome cell
line LNCaP). Sequence analysis by automatic sequencing
with the same sense and antisense primers revealed coin-
cidence with human AVP, ER, ER, and AR mRNA
sequences, respectively.
AVP mRNA levels were up-regulated by estradiol
in SH-SY5Y neuronal cells by a mechanism blocked
by an ER antagonist and enhanced by an ER
antagonist
SH-SY5Y cells were treated with either vehicle or es-
tradiol for 24hours. Estradiol treatment at concentrations
of 107 and 108 M did not significantly affect AVP
mRNA levels. However, a significant increase in AVP
mRNA levels was detected when the cells were treated
with 109 or 1010M estradiol. Themaximal effect was
observed at 109 M (Figure 2A). Treatment with ER
antagonists MPP, PHTPP, and ICI 182,780 alone, did
not affect AVP mRNA levels (data not shown). How-
ever, the effect of estradiol was blocked by the ER
antagonist MPP (Figure 2B) and by the ER antagonist
ICI 182,780 (Figure 2C) but not by the ER antagonist
PHTPP (Figure 2E). In addition, the combination of
estradiol with the ER antagonist MPP at 107 M re-
sulted in significantly lower AVP mRNA levels com-
pared with control values. In contrast, the combination
of estradiol with the ER antagonist PHTPP at 107 M
resulted in significantly higher AVP mRNA levels com-
pared with estradiol values (Figure 2, B and D). A pos-
sible interpretation of these results is that estradiol is
acting on both ERs, enhancing or decreasing AVP
mRNA levels through ER or ER, respectively. To test
this hypothesis, in the next experiment, cells were
treated with an ER or an ER agonist.
AVP mRNA levels were up-regulated by an ER
agonist and down-regulated by an ER agonist in
SH-SY5Y neuronal cells
As shown in Figure 2E, treatment of SH-SY5Y cells
with the ER agonist PPT, at 108 M, resulted in a sig-
nificant increase inAVPmRNAlevels comparedwith con-
trol values. In contrast, the treatmentwith theERagonist
DPN, at 107M, resulted in a significant decrease in AVP
mRNA levels (Figure 2F). The enhancement of AVP
mRNA levels by PPT was stronger than the decrease in
Figure 1. PCR analysis of ER, ER, and AVP in SH-SY5Y human
neuroblastoma cells.
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AVP mRNA levels caused by DPN. This finding further
indicates that ER and ER have opposite effects on AVP
mRNA levels in SH-SY5Y cells.
AVP mRNA levels in SH-SY5Y
neuronal cells were up-
regulated by T by a mechanism
independent of its conversion
to 5-DHT and the consequent
activation of AR
T, at 108 M, significantly in-
creasedAVPmRNAinSH-SY5Ycells
compared with control cells (Figure
3A). One possible mechanism of ac-
tion of the hormone is by its conver-
sion in 5-DHT and the activation of
AR. Although we did not detect AR
mRNA in our cells, previous studies
have reported that SH-SY5Y cells me-
tabolize T in 5-DHT (44) and ex-
press AR (45). Thus, we explored this
possiblemechanismofregulation.The
T-induced AVP mRNA increase was
not affected when cells were treated
with finasteride, an inhibitor of 5-re-
ductase, the enzyme that converts T in
5-DHT (Figure 3B). Furthermore,
the action of T was not affected when
cells were treated with the AR antag-
onist flutamide (Figure 3C). Finas-
teride and flutamide alone did not sig-
nificantly affect AVP mRNA levels
(data not shown).
To further exclude the possible im-
plication of AR in the action of T, SH-
SY5Y cells were treated with the AR
agonist 5-DHT. 5-DHT treatment,
at concentrations ranging from 107
to109M,notonlydidnot imitate the
effect of T but also even had an oppo-
site effect, resulting in a significant de-
crease inAVPmRNAlevels compared
with control values (Figure 3D). The
effect of 5-DHTwas not affected by
flutamide (Figure 3E). These findings
suggest that T and 5-DHT regulate
AVPmRNAlevels inSH-SY5Ycells in
opposite ways and by mechanisms
that are independent of AR.
AVP mRNA levels in SH-SY5Y
neuronal cells were down-
regulated by the 5-DHT
metabolite 3-diol
In the previous experiments, we observed that both 5-
DHT and the ER agonist DPN exerted an inhibitory ac-
Figure 2. AVP mRNA levels in SH-SY5Y human neuroblastoma cells. A, Cells were treated
for 24 hours with vehicle (control) or different doses of 17-estradiol (E2). ANOVA: F (4, 19) 
221.3; P  .0001. B, Cells were treated for 24 hours with vehicle, 109 M E2, or 109 M E2
and different doses of the ER antagonist MPP. ANOVA: F (5, 17)  12.53.3; P  .0002. C,
Cells were treated for 24 hours with vehicle, 109 M E2, or 109 M E2 and the ER
antagonist ICI 182,780 (ICI; 108 M). ANOVA: F (4, 14)  175.9; P  .001. D, Cells were
treated for 24 hours with vehicle, 109 M E2, or 109 M E2 and different doses of the ER
antagonist PHTPP. ANOVA: F (5, 17)  16.84; P  .0001. E, Cells were treated for 24 hours
with vehicle or different doses of the ER agonist PPT. ANOVA: F (4, 21)  25.03; P  .0001.
F, Cells were treated for 24 hours with vehicle or different doses of the ER agonist DPN.
ANOVA: F (4, 23)  6.78; P  .0014. Data are represented as the mean  SEM. Results of the
Bonferroni’s test: significant differences of *, P  .05 and ***, P  .001 vs the control
value; ˆ, P  .05, ˆˆ, P  .01, and ˆˆˆ, P  .001 vs the estradiol value.
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tion on AVP mRNA levels in SH-SY5Y cells. Therefore, a
possible mechanism for the action of 5-DHT is the activa-
tion of ER after its conversion in its metabolite 3-diol.
Thus, we treated SH-SY5Y cells with 3-diol to determine
whether this steroid regulates AVP
mRNAlevels.3-Diol significantlyre-
duced AVP mRNA levels but only at
high concentration (106 M).
AVP mRNA levels in SH-SY5Y
neuronal cells were up-regulated
by T by a mechanism blocked by
an aromatase inhibitor and an
ER antagonist
We had previously observed that
our SH-SY5Y cell line expresses the
enzyme aromatase (42), which con-
vertsT in estradiol.Therefore,Tmay
potentially affect AVP mRNA levels
by the activation of ERs after its con-
version into estradiol. To test this hy-
pothesis, SH-SY5Ycellswere treated
withT in thepresenceof letrozole, an
aromatase inhibitor. Under these
conditions, T not only did not in-
crease but also even resulted in a sig-
nificant decrease in AVPmRNA lev-
els (Figure 4A). This finding
suggested that T up-regulates AVP
mRNA levels by its conversion in es-
tradiol. To further test this possibil-
ity, SH-SY5Y cells were treated with
T in the presence or absence of ER
antagonists. Interestingly, the up-
regulation ofAVPmRNA levels byT
was blocked by the ER antagonist
MPP and by the ER antagonist ICI
182,780 (Figure 4B). The combina-
tion of T with the ER antagonist
MPP resulted in a significant de-
crease of AVP mRNA levels com-
pared with control values, suggest-
ing a possible inhibitory action of
ER. However, the ER antagonist
PHTPP did not affect the up-regula-
tion of AVP mRNA levels by T (Fig-
ure 4B). These findings suggest that
T up-regulated AVPmRNA levels in
SH-SY5Y cells after its conversion to
estradiol and the consequent activa-
tion of ER.
Discussion
AVP is synthesized by different neuronal populations of
the central nervous system. AVP synthesized by the mag-
Figure 3. AVP mRNA levels in SH-SY5Y human neuroblastoma cells. A, Cells were treated for
24 hours with vehicle (control) or different doses of T. ANOVA: F (5, 17)  9.648; P  .0007. B,
Cells were treated for 24 hours with vehicle, 108 M T, or 108 M T and different doses of the
5-reductase inhibitor finasteride (Fin). ANOVA: F (6, 20)  60.14; P  .0001. C, Cells were
treated for 24 hours with vehicle, 108 M T, or 108 M T and different doses of the androgen
receptor antagonist flutamide (Flut). ANOVA: F (6, 20)  15.60; P  .0001. D, Cells were treated
for 24 hours with vehicle or with different doses of 5-DHT. ANOVA: F (5, 18)  4.495; P 
.0134. E, Cells were treated for 24 hours with vehicle, 108 M 5-DHT, or 108 M 5-DHT and
different doses of the of the androgen receptor antagonist flutamide (Flut). ANOVA: F (6, 21) 
9.402; P  .0002. F, Cells were treated for 24 hours with vehicle or different doses of the ER
agonist 3diol. ANOVA: F (4, 18)  48.18; P  .0001. Data are represented as the mean  SEM.
Results of the Bonferroni’s test: significant differences of *, P  .05, **, P  .01, and ***, P 
.001 vs the control value.
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nocellular neurons of the paraventricular and supraoptic
nuclei (46) is released in the neurohypophysis and exert
hormonal actions, regulating water balance. AVP synthe-
sized by other neuronal groups, such as the bed nucleus of
the stria terminalis, medial amygdala, suprachiasmatic
nucleus, and the parvocellular neurons from the paraven-
tricular nucleus (47) act as a neuromodulator and partic-
ipates in the regulation of circadian rhythms, cardiovas-
cular function, the stress response, social recognition,
social behavior, and attachment (1, 48–51). These behav-
iors and physiological processes are modulated by estra-
diol and T, which also regulate AVP expression in the
brain bymechanismsnot fully elucidated. In this study,we
have used SH-SY5Y human neuroblastoma cells to assess
the role of ERs on the regulation of AVP expression. We
have first shown that SH-SY5Y cells express AVP, ER,
and ER, therefore being an adequate cellular model for
our aims.
Our findings indicate that estradiol increases AVP ex-
pression in SH-SY5Y cells. This effect of estradiol was
imitatedby anER agonist, PPT, andwasblockedbyboth
an ER antagonist, ICI 182,780, and an ER antagonist,
MPP. In contrast, an ER agonist, DPN, reduced AVP
expression in SH-SY5Y cells. In addition, the ER antag-
onist MPP caused a significant reduction in AVP mRNA
levels, whereas the ER antagonist PHTPP enhanced the
action of estradiol onAVP expression. These findings sug-
gest that estradiol is acting on both ERs to regulate AVP
expression with opposite effects, enhancing AVP expres-
sion via ER anddecreasingAVP expression via ER. The
action on ER predominates at low concentrations of the
hormone (109 to1010M), and the result is anet increase
in AVP expression after estradiol treatment. However, at
higher concentrations (108 to 107M), estradiol no lon-
ger increases AVP expression. This may in part reflect the
activation of ER, which compensates the transcriptional
action of ER. Our findings are in agreement with previ-
ous studies showing that estradiol induces transcriptional
activation of the AVP gene in SK-N-SH cells transfected
with ER, whereas the hormone reduces transcriptional
activation of the AVP gene in SK-N-SH cells transfected
with ER (52). Although the stimulatory effect of ER on
the AVP promoter involves estrogen response elements,
the action of ER at activator protein-1 sites (52, 53) may
be involved in the inhibitory effect of ER on the AVP
promoter.
Thedifferent effect of ER andERonAVPexpression
is of physiological relevance. For instance, estradiol de-
creases AVP transcript levels in male mice PVN, a region
in which the main ER form is ER, and this action is
abolished in ER knockout mice (25). Our present find-
ings, showing that the activation of ER decreases AVP
mRNA levels, are in agreementwith this observation.Our
results are also relevant for the estrogenic regulation of
AVP in other brain regions such as the bed nucleus of the
stria terminalis, the medial nucleus of the amygdala, and
the periventricular preoptic nucleus, in which both ER
and ER are expressed (54).
In male and female rodents, the in vivo expression of
AVP is down-regulated by gonadectomy andup-regulated
by T in the bed nucleus of the stria terminalis and medial
amygdala (28, 55–57). Our present findings indicate that
T up-regulates AVP expression in SH-SY5Y cells. SH-
SY5Ycells express the enzyme5-reductase and are there-
fore able to convert T in the AR agonist 5-DHT (44).
Although we have not been able to detect AR mRNA in
our cells, a previous study has reported the expression of
Figure 4. AVP mRNA levels in SH-SY5Y human neuroblastoma cells.
A, Cells were treated for 24 hours with vehicle (control), 108 M T, or
108 M T and different doses of the aromatase inhibitor letrozole
(Letr). ANOVA: F (5, 21)  85.76; P  .0001. B, Cells were treated for
24 hours with vehicle, 108 M T, 108 M T and 107 M MPP (ER
antagonist), 108 M T and 107 M PHTPP (ER antagonist), and 108
M T and 108 M ICI 182,780 (ICI; ER antagonist). Results of the
Bonferroni’s test: significant differences of *, P  .05 and ***, P 
.001 vs the control value; ˆˆˆ, P  .001 vs the T value.
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AR in the SH-SY5Y cell line (45). Therefore, to fully ex-
clude the possible implication of AR in the action of T, we
used the 5-reductase inhibitor finasteride, the AR antag-
onist flutamide, and theARagonist 5-DHT.The effect of
TonAVPexpressionwas not affected by these treatments,
indicating thatAR is not involved in the regulation ofAVP
expression by T in the SH-SY5Y cells.
SH-SY5Y cells express aromatase (42); therefore, T
may be converted to estradiol in these cells. Interest-
ingly, the effect of T on AVP expression in SH-SY5Y
cells was blocked by an aromatase inhibitor and by an
ER antagonist. This suggests that T regulates AVP ex-
pression in SH-SY5Y cells by its conversion to estradiol
and the activation of ER. In contrast to T, 5-DHT
decreased AVP expression in SH-SY5Y cells. This effect
of 5-DHT was not affected by flutamide and therefore
seems to be independent from AR. It is known that
5-DHT can be converted to the androgen metabolite
3-diol, which is an agonist of ER (58–61). Interest-
ingly, the ER agonist DPN had a similar effect to 5-
DHT in reducing AVP expression. Therefore, one of the
possible mechanisms involved in the regulation of AVP
expression by 5-DHT is the conversion to the andro-
gen metabolite 3-diol and the activation of ER (39,
40). Indeed, we detected that 3-diol decreased AVP
mRNA levels in SH-SY5Y cells.
A question raised by our findings is the interpretation
of the results obtained with the ER antagonist ICI
182,780. In the cells treated with estradiol or T and ICI
182,780, AVP mRNA levels were not different from con-
trol values. This is in contrast with the effects of 107 M
MPP and 107MPHTPP in the presence of estradiol or T,
decreasing and increasing AVP expression, respectively.
One possible interpretation is that ICI 182,780 blocked
the ER-induced increase and the ER-induced decrease
in AVP mRNA levels, resulting in a net zero effect. This
suggests that inother systems thedifferential regulationby
ER and ER may not be fully appreciated by using ICI
182,780.
In summary, our findings indicate that estradiol regu-
lates AVP expression in the SH-SY5Y cells through both
ERs, exerting a stimulatory action via ER and an inhib-
itory action via ER. In addition, the regulation of AVP
expression in the SH-SY5Ycells byT is independent ofAR
and involves, as for estradiol, a stimulatory action viaER
and an inhibitory action via ER. These data suggest that
distinct AVP neuronal populations coexpressing different
relative levels of ER and ER may be differentially reg-
ulated by gonadal hormones.
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